Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Investment Income (2018 - 2021)

Lineage Cell Therapeutics' Non Operating Investment Income history spans 4 years, with the latest figure at $6.0 million for Q1 2021.

  • For Q1 2021, Non Operating Investment Income rose 378.86% year-over-year to $6.0 million; the TTM value through Dec 2021 reached $6.0 million, up 32.11%, while the annual FY2021 figure was $6.0 million, 32.11% up from the prior year.
  • Non Operating Investment Income reached $6.0 million in Q1 2021 per LCTX's latest filing, up from $712000.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $6.0 million in Q1 2021 to a low of -$5.0 million in Q4 2019.
  • Average Non Operating Investment Income over 4 years is $782153.8, with a median of $523000.0 recorded in 2018.
  • The largest YoY upside for Non Operating Investment Income was 8834.78% in 2019 against a maximum downside of 1047.04% in 2019.
  • A 4-year view of Non Operating Investment Income shows it stood at $523000.0 in 2018, then tumbled by 1047.04% to -$5.0 million in 2019, then soared by 114.38% to $712000.0 in 2020, then surged by 746.07% to $6.0 million in 2021.
  • Per Business Quant, the three most recent readings for LCTX's Non Operating Investment Income are $6.0 million (Q1 2021), $712000.0 (Q4 2020), and $120000.0 (Q3 2020).